

Serial No. 09/842,337

AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

IN THE SPECIFICATION

Please replace the paragraph beginning on page 1, line 4, with the following rewritten paragraph:

b¹ - This application is a continuation of U.S. Patent Application No. 09/444,479, which now is patent U.S. 6,270,764 B1 issued on August 7, 2001.-

IN THE CLAIMS

Please add the following claims:

11. (New) The method of Claim 1 which comprises administering to said patient a dosage of about 5 µg/kg/hr to about 250 µg/kg/hr.

b² 12. (New) The method of Claim 11 which comprises administering to said patient said dosage as continuous infusion for about 1 hour to about 240 hours.

13. (New) A formulation used in the treatment of viral hemorrhagic fever comprising human protein C zymogen, a bulking agent, a salt, and a buffer.

14. (New) The formulation of Claim 13 wherein the bulking agent is sucrose, the salt is sodium chloride, and the buffer is sodium citrate.

REMARKS

Viral hemorrhagic fever is a clinical syndrome associated with significant mortality. Disease severity at its most extreme includes circulatory instability, increased vascular permeability, and diffuse hemorrhage. While the